Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.77 billion, which missed the consensus of $3.94 billion, up 17% on a reported basis, 23% on a constant currency basis, and rising slightly on an operational basis.
Adjusted EPS of $0.82 came in line with the consensus and the management guidance of $0.79- $0.83.
Renal Care, Clinical Nutrition, and Advanced Surgery delivered mid-single-digit growth.
Medication Delivery performance was comparable to the same period in 2021. Growth was partially offset by a low single-digit decline in Pharmaceuticals, primarily due to generic competition.
Acute Therapies and BioPharma Solutions declined, reflecting challenging comparisons due to a return to normal sales following increased COVID-19-related sales in Q3 FY21.
Outlook: Baxter expects FY22 adjusted EPS of $3.53-3.60, lower than prior guidance of $3.60 - $3.70 versus the consensus of $3.62.
The company forecasts sales growth of 17%-18% on a reported basis, approximately 23% on a constant currency basis, and low single digits on an operational basis.
For Q4 FY22, Baxter sees sales growth of mid-to-high single digits on a reported basis, mid-teens on a constant currency basis, and approximately flat on an operational basis.
It sees FY22 Adj. EPS of $0.92-$0.99 vs. the consensus estimate of $1.00.
Price Action: BAX shares are down 6.35% at $53.97 on the last check Thursday.
See more from Benzinga
Community Health Systems Shares Are Trading Higher After Q3 Earnings
Ensign Group Lifts FY22 Outlook On Higher Occupancies, Skilled Mix, Reimbursement
Garry Kasparov Says Rishi Sunak's First Phone Call As UK PM Was To 'The Leader Of The Free World' — It Wa
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
